Tumor-targeting glycol chitosan nanoparticles as a platform delivery carrier in cancer diagnosis and therapy

Nanomedicine

Volumn 9, Issue 11, 2014, Pages 1697-1713

  Lee, So Jin ^a   Min, Hyun Su ^a   Ku, Sook Hee ^a   Son, Sohee ^a   Kwon, Ick Chan ^a,b   Kim, Sun Hwa ^a   Kim, Kwangmeyung ^a  

^a Korea Institute of Science and Technology   (South Korea)

^b Korea University   (South Korea)

Author keywords

amphiphilic nanoparticles; cancer therapy; diagnosis; EPR; glycol chitosan

Indexed keywords

GLYCOL CHITOSAN NANOPARTICLE; NANOPARTICLE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CHITOSAN; DRUG CARRIER; GLYCOL-CHITOSAN; SERUM ALBUMIN; SMALL INTERFERING RNA;

CANCER DIAGNOSIS; CANCER THERAPY; DIAGNOSTIC IMAGING; DRUG DELIVERY SYSTEM; DRUG TARGETING; IN VITRO STUDY; IN VIVO STUDY; REVIEW; ANIMAL; CELL LINE; CHEMISTRY; CONFOCAL MICROSCOPY; GENE THERAPY; HELA CELL LINE; HUMAN; METABOLISM; MOLECULAR WEIGHT; MOUSE; NANOMEDICINE; NEOPLASMS; PERMEABILITY; PHOTOCHEMOTHERAPY; PROCEDURES; UMBILICAL VEIN ENDOTHELIAL CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE; CHITOSAN; DRUG CARRIERS; GENETIC THERAPY; HELA CELLS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MICE; MICROSCOPY, CONFOCAL; MOLECULAR WEIGHT; NANOMEDICINE; NANOPARTICLES; NEOPLASMS; PERMEABILITY; PHOTOCHEMOTHERAPY; RNA, SMALL INTERFERING; SERUM ALBUMIN;

EID: 84908866688     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.14.99     Document Type: Review

References (68)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J. Clin. 61 (2), 69-90 (2011).
2. Cassileth BR, Deng G. Complementary and Alternative Therapies for Cancer. Oncologist 9 (1), 80-89 (2004).
3. Singhal V, Singh J, Lyall A, Saxena S, Bansal A. Is drug-induced toxicity a good predictor of response to neo-adjuvant chemotherapy in patients with breast cancer? A prospective clinical study. BMC Cancer 4 (1), 48 (2004).
4. Morelli D, Ménard S, Colnaghi MI, Balsari A. Oral administration of anti-doxorubicin monoclonal antibody prevents chemotherapy-induced gastrointestinal toxicity in mice. Cancer Res. 56 (9), 2082-2085 (1996).
5. Zhang D, Hedlund E-ME, Lim S Antiangiogenic agents significantly improve survival in tumor-bearing mice by increasing tolerance to chemotherapy-induced toxicity. Proc. Natl Acad. Sci. USA 108 (10), 4117-4122 (2011).
6. Suresh S. Nanomedicine: elastic clues in cancer detection. Nat. Nanotechnol. 2 (12), 748-749 (2007).
7. Liu Y, Miyoshi H, Nakamura M. Nanomedicine for drug delivery and imaging: a promising avenue for cancer therapy and diagnosis using targeted functional nanoparticles. Int. J. Cancer 120 (12), 2527-2537 (2007).
8. Cheng Y, Samia AC, Li J, Kenney ME, Resnick A, Burda C. Delivery and efficacy of a cancer drug as a function of the bond to the gold nanoparticle surface. Langmuir 26 (4), 2248-2255 (2009).
9. Perrault SD, Chan WC. In vivo assembly of nanoparticle components to improve targeted cancer imaging. Proc. Natl Acad. Sci. USA 107 (25), 11194-11199 (2010).
10. Estévez MC, Huang Y-F, Kang H Nanoparticle-aptamer conjugates for cancer cell targeting and detection. In: Cancer Nanotechnol. (Volume 624). Grobmyer SR & Moudgil BM (Eds)., Humana Press, NY, USA, 235-248 (2010).
11. Ruoslahti E, Bhatia SN, Sailor MJ. Targeting of drugs and nanoparticles to tumors. J. Cell Biol. 188 (6), 759-768 (2010).
12. Kim K, Kim JH, Park H Tumor-homing multifunctional nanoparticles for cancer theragnosis: simultaneous diagnosis, drug delivery, and therapeutic monitoring. J. Control. Release 146 (2), 219-227 (2010).
13. Byrne JD, Betancourt T, Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv. Drug Del. Rev. 60 (15), 1615-1626 (2008).
14. Cho K, Wang X, Nie S, Shin DM. Therapeutic nanoparticles for drug delivery in cancer. Clin. Cancer. Res. 14 (5), 1310-1316 (2008).
15. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2 (12), 751-760 (2007).
16. Bhaskar S, Tian F, Stoeger T Multifunctional nanocarriers for diagnostics, drug delivery and targeted treatment across blood-brain barrier: perspectives on tracking and neuroimaging. Part. Fibre Toxicol. 7 (3), 3 (2010).
17. Prabaharan M. Review Paper: chitosan derivatives as promising materials for controlled drug delivery. J. Biomater. Appl. 23 (1), 5-36 (2008).
18. Felt O, Buri P, Gurny R. Chitosan: a unique polysaccharide for drug delivery. Drug Dev. Ind. Pharm. 24 (11), 979-993 (1998).
19. Park JH, Saravanakumar G, Kim K, Kwon IC. Targeted delivery of low molecular drugs using chitosan and its derivatives. Adv. Drug Del. Rev. 62 (1), 28-41 (2010).
20. Wang JJ, Zeng ZW, Xiao RZ Recent advances of chitosan nanoparticles as drug carriers. Int. J. Nanomed. 6, 765 (2011).
21. Kean T, Thanou M. Biodegradation, biodistribution and toxicity of chitosan. Adv. Drug Del. Rev. 62 (1), 3-11 (2010).
22. Agnihotri SA, Mallikarjuna NN, Aminabhavi TM. Recent advances on chitosan-based micro-and nanoparticles in drug delivery. J. Control. Release 100 (1), 5-28 (2004).
23. Pan Y, Li Y-J, Zhao H-Y Bioadhesive polysaccharide in protein delivery system: chitosan nanoparticles improve the intestinal absorption of insulin in vivo. Int. J. Pharm. 249 (1), 139-147 (2002).
24. Rudzinski WE, Aminabhavi TM. Chitosan as a carrier for targeted delivery of small interfering RNA. Int. J. Pharm. 399 (1-2), 1-11 (2010).
25. Peng H, Li W, Ning F Amphiphilic chitosan derivatives-based liposomes: synthesis, development and properties as a carrier for sustained release of salidroside. J. Agric. Food Chem. 62 (3), 626-633 (2014).
26. Viegas De Souza RHF, Takaki M, De Oliveira Pedro R, Dos Santos Gabriel J, Tiera MJ, De Oliveira Tiera VA. Hydrophobic effect of amphiphilic derivatives of chitosan on the antifungal activity against Aspergillus flavus and Aspergillus parasiticus. Molecules 18 (4), 4437-4450 (2013).
27. Kim K, Kim J-H, Kim S Self-assembled nanoparticles of bile acid-modified glycol chitosans and their applications for cancer therapy. Macromol. Res. 13 (3), 167-175 (2005).
28. Yu JM, Li YJ, Qiu LY, Jin Y. Polymeric nanoparticles of cholesterol-modified GC for doxorubicin delivery: preparation and in-vitro and in-vivo characterization. J. Pharm. Pharmacol. 61 (6), 713-719 (2009).
29. Kim JH, Kim YS, Park K Antitumor efficacy of cisplatin-loaded GC nanoparticles in tumor-bearing mice. J. Control. Release 127 (1), 41-49 (2008).
30. Hwang H-Y, Kim I-S, Kwon IC, Kim Y-H. Tumor targetability and antitumor effect of docetaxel-loaded hydrophobically modified GC nanoparticles. J. Control. Release 128 (1), 23-31 (2008).
31. Min KH, Park K, Kim Y-S Hydrophobically modified GC nanoparticles-encapsulated camptothecin enhance the drug stability and tumor targeting in cancer therapy. J. Control. Release 127 (3), 208-218 (2008).
32. Kim J-H, Kim Y-S, Kim S Hydrophobically modified GC nanoparticles as carriers for paclitaxel. J. Control. Release 111 (1), 228-234 (2006).
33. Na JH, Koo H, Lee S Real-time and non-invasive optical imaging of tumor-targeting GC nanoparticles in various tumor models. Biomaterials 32 (22), 5252-5261 (2011).
34. Hillaireau H, Couvreur P. Nanocarriers' entry into the cell: relevance to drug delivery. Cell. Mol. Life Sci. 66 (17), 2873-2896 (2009).
35. Nam HY, Kwon SM, Chung H Cellular uptake mechanism and intracellular fate of hydrophobically modified GC nanoparticles. J. Control. Release 135 (3), 259-267 (2009).
36. Park K, Kim JH, Nam YS Effect of polymer molecular weight on the tumor targeting characteristics of self-assembled GC nanoparticles. J. Control. Release 122 (3), 305-314 (2007).
37. Na JH, Lee SY, Lee S Effect of the stability and deformability of self-assembled GC nanoparticles on tumor-targeting efficiency. J. Control. Release 163 (1), 2-9 (2012).
38. Yuk SH, Oh KS, Cho SH Glycol chitosan/heparin immobilized iron oxide nanoparticles with a tumor-targeting characteristic for magnetic resonance imaging. Biomacromolecules 12 (6), 2335-2343 (2011).
39. Crayton SH, Tsourkas A. pH-titratable superparamagnetic iron oxide for improved nanoparticle accumulation in acidic tumor microenvironments. ACS Nano 5 (12), 9592-9601 (2011).
40. De Luca E, Harvey P, Chalmers KH Characterisation and evaluation of paramagnetic fluorine labelled GC conjugates for F and H magnetic resonance imaging. J. Biol. Inorg. Chem. 19 (2), 215-227 (2013).
41. Nam T, Park S, Lee S-Y Tumor targeting chitosan nanoparticles for dual-modality optical/MR cancer imaging. Bioconj. Chem. 21 (4), 578-582 (2010).
42. Sun IC, Eun DK, Koo H Tumor-targeting gold particles for dual computed tomography/optical cancer imaging. Angew. Chem. Int. Ed. 50 (40), 9348-9351 (2011).
43. Sun IC, Na JH, Jeong SY Biocompatible glycol chitosan-coated gold nanoparticles for tumor-targeting CT imaging. Pharm. Res. 1-8 (2013).
44. Kim DE, Kim JY, Sun IC Hyperacute direct thrombus imaging using computed tomography and gold nanoparticles. Ann. Neurol. 73 (5), 617-625 (2013).
45. Lee D-E, Na JH, Lee S Facile method to radiolabel GC nanoparticles with 64Cu via copper-free click chemistry for microPET imaging. Mol. Pharm. 10 (6), 2190-2198 (2013).
46. Kang E, Min HS, Lee J Nanobubbles from gas-generating polymeric nanoparticles: ultrasound imaging of living subjects. Angew. Chem. Int. Ed. 49 (3), 524-528 (2010).
47. Koo H, Min KH, Lee SC Enhanced drug-loading and therapeutic efficacy of hydrotropic oligomer-conjugated GC nanoparticles for tumor-targeted paclitaxel delivery. J. Control. Release 172 (3), 823-831 (2013).
48. Son YJ, Jang J-S, Cho YW Biodistribution and anti-tumor efficacy of doxorubicin loaded glycol-chitosan nanoaggregates by EPR effect. J. Control. Release 91 (1), 135-145 (2003).
49. Lee BS, Park K, Park S Tumor targeting efficiency of bare nanoparticles does not mean the efficacy of loaded anticancer drugs: importance of radionuclide imaging for optimization of highly selective tumor targeting polymeric nanoparticles with or without drug. J. Control. Release 147 (2), 253-260 (2010).
50. Meng L, Huang W, Wang D, Huang X, Zhu X, Yan D. Chitosan-based nanocarriers with pH and light dual response for anticancer drug delivery. Biomacromolecules 14 (8), 2601-2610 (2013).
51. Kim JH, Kim YS, Park K Self-assembled GC nanoparticles for the sustained and prolonged delivery of antiangiogenic small peptide drugs in cancer therapy. Biomaterials 29 (12), 1920-1930 (2008).
52. Lee SJ, Koo H, Jeong H Comparative study of photosensitizer loaded and conjugated GC nanoparticles for cancer therapy. J. Control. Release 152 (1), 21-29 (2011).
53. Lee SJ, Koo H, Lee DE Tumor-homing photosensitizer-conjugated GC nanoparticles for synchronous photodynamic imaging and therapy based on cellular on/off system. Biomaterials 32 (16), 4021-4029 (2011).
54. Oh IH, Min HS, Li L Cancer cell-specific photoactivity of pheophorbide a-glycol chitosan nanoparticles for photodynamic therapy in tumor-bearing mice. Biomaterials 34 (27), 6454-6463 (2013).
55. Kim S, Lee DJ, Kwag DS, Lee UY, Youn YS, Lee ES. Acid pH-activated glycol chitosan/fullerene nanogels for efficient tumor therapy. Carbohydr. Polym. 101, 692-698 (2014).
56. Kwag DS, Oh NM, Oh YT, Oh KT, Youn YS, Lee ES. Photodynamic therapy using GC grafted fullerenes. Int. J. Pharm. 431 (1-2), 204-209 (2012).
57. Yoo HS, Lee JE, Chung H, Kwon IC, Jeong SY. Self-assembled nanoparticles containing hydrophobically modified GC for gene delivery. J. Control. Release 103 (1), 235-243 (2005).
58. Huh MS, Lee SY, Park S Tumor-homing glycol chitosan/polyethylenimine nanoparticles for the systemic delivery of siRNA in tumor-bearing mice. J. Control. Release 144 (2), 134-143 (2010).
59. Lee SJ, Huh MS, Lee SY Tumor-homing poly-siRNA/glycol chitosan self-cross-linked nanoparticles for systemic siRNA delivery in cancer treatment. Angew. Chem. Int. Ed. 51 (29), 7203-7207 (2012).
60. Park JH, Kwon S, Nam J-O Self-assembled nanoparticles based on GC bearing 5β-cholanic acid for RGD peptide delivery. J. Control. Release 95 (3), 579-588 (2004).
61. Dolmans DE, Fukumura D, Jain RK. Photodynamic therapy for cancer. Nat. Rev. Cancer 3 (5), 380-387 (2003).
62. Al-Dosari MS, Gao X. Nonviral gene delivery: principle, limitations, and recent progress. The AAPS journal 11 (4), 671-681 (2009).
63. Köping-Högrd M, Tubulekas I, Guan H Chitosan as a nonviral gene delivery system. Structure-property relationships and characteristics compared with polyethylenimine in vitro and after lung administration in vivo. Gene Ther. 8 (14), (2001).
64. Köping-Högrd M, Vrum K, Issa M Improved chitosan-mediated gene delivery based on easily dissociated chitosan polyplexes of highly defined chitosan oligomers. Gene Ther. 11 (19), 1441-1452 (2004).
65. Hannon GJ. RNA interference. Nature 418 (6894), 244-251 (2002).
66. Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat. Rev. Drug Discov. 8 (2), 129-138 (2009).
67. Lee SJ, Son S, Yhee JY Structural modification of siRNA for efficient gene silencing. Biotechnol. Adv. 31 (5), 491-503 (2013).
68. Lee S-Y, Huh MS, Lee S Stability and cellular uptake of polymerized siRNA (poly-siRNA)/polyethylenimine (PEI) complexes for efficient gene silencing. J. Control. Release 141 (3), 339-346 (2010).